Search
Gransun Receives Ethical Approval for Phase III Clinical Trial of Revolutionary Hepatitis B Treatment, Nercavir (GST-HG141)
3 day ago /
Read about 0 minute
Author：小编
Gransun has announced that its innovative drug subsidiary, Gransun Zhonglin, has secured ethical approval for the Phase III clinical trial of Nercavir (GST-HG141), a groundbreaking treatment for hepatitis B. Nercavir represents a novel class of drugs, specifically a hepatitis B core protein/nucleocapsid modulator, with an entirely new mechanism of action. Gransun holds exclusive global intellectual property rights for this pioneering medication. Nevertheless, GST-HG141 must still undergo registrational clinical research and attain national approval prior to its commercial launch.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
